De-Fu Ma1, Li-Qiang Qin, Pei-Yu Wang, Ryohei Katoh. 1. Department of Social Medicine & Health Education, School of Public Health, Peking University, Beijing 100083, PR China.
Abstract
BACKGROUND & AIMS: The effects of isoflavones on bone loss appear inconsistent in randomized controlled trials. Therefore, we used a statistical method of combining these diverse data to clarify the effects of soy isoflavone intake on spine bone loss. METHODS: We identified randomized controlled trials related to the effects of soy isoflavone intake on spine bone mineral density or spine bone mineral content and performed meta-analysis with Review Manager 4.2 software. RESULTS: Ten studies with a total of 608 subjects were selected for meta-analysis. The spine bone mineral density in subjects who consumed isoflavones increased significantly by 20.6 mg/cm(2) (95% confidence interval: 4.5-36.6 mg/cm(2)) in comparison to that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake increased spine bone mineral content by 0.93 g (95% confidence interval: -0.37 to 2.24 g) with borderline significance. Increases in the spine bone mineral density with isoflavone intake of more than 90 mg/day and with treatment lasting 6 months were 28.5mg/cm(2) (95% confidence interval: 8.4-48.6 mg/cm(2)) and 27 mg/cm(2) (95% confidence interval: 8.3-45.8 mg/cm(2)), respectively. CONCLUSIONS: Isoflavone intervention significantly attenuates bone loss of the spine in menopausal women. These favorable effects become more significant when more than 90 mg/day of isoflavones are consumed. And soy isoflavone consumption for 6 months can be enough to exert beneficial effects on bone in menopausal women.
BACKGROUND & AIMS: The effects of isoflavones on bone loss appear inconsistent in randomized controlled trials. Therefore, we used a statistical method of combining these diverse data to clarify the effects of soy isoflavone intake on spine bone loss. METHODS: We identified randomized controlled trials related to the effects of soy isoflavone intake on spine bone mineral density or spine bone mineral content and performed meta-analysis with Review Manager 4.2 software. RESULTS: Ten studies with a total of 608 subjects were selected for meta-analysis. The spine bone mineral density in subjects who consumed isoflavones increased significantly by 20.6 mg/cm(2) (95% confidence interval: 4.5-36.6 mg/cm(2)) in comparison to that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake increased spine bone mineral content by 0.93 g (95% confidence interval: -0.37 to 2.24 g) with borderline significance. Increases in the spine bone mineral density with isoflavone intake of more than 90 mg/day and with treatment lasting 6 months were 28.5mg/cm(2) (95% confidence interval: 8.4-48.6 mg/cm(2)) and 27 mg/cm(2) (95% confidence interval: 8.3-45.8 mg/cm(2)), respectively. CONCLUSIONS:Isoflavone intervention significantly attenuates bone loss of the spine in menopausal women. These favorable effects become more significant when more than 90 mg/day of isoflavones are consumed. And soy isoflavone consumption for 6 months can be enough to exert beneficial effects on bone in menopausal women.
Authors: William W Wong; Richard D Lewis; Francene M Steinberg; Michael J Murray; Margaret A Cramer; Paula Amato; Ronald L Young; Stephen Barnes; Kenneth J Ellis; Roman J Shypailo; J Kennard Fraley; Karen L Konzelmann; Joan G Fischer; E O'Brian Smith Journal: Am J Clin Nutr Date: 2009-09-16 Impact factor: 7.045
Authors: C M Weaver; B R Martin; G S Jackson; G P McCabe; J R Nolan; L D McCabe; S Barnes; S Reinwald; M E Boris; M Peacock Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958